Opening book details…
About this Medicine article
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial by Di Cosimo, S.; Sathyanarayanan, S.; Bendell, J. C.; Cervantes, A.; Stein, M. N.; Brana, I.; Roda, D.; Haines, B. B.; Zhang, T.; Winter, C. G.; Jha, S.; Xu, Y.; Frazier, J.; Klinghoffer, R. A.; Leighton-Swayze, A.; Song, Y.; Ebbinghaus, S.; Baselga, J. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Di Cosimo, S.; Sathyanarayanan, S.; Bendell, J. C.; Cervantes, A.; Stein, M. N.; Brana, I.; Roda, D.; Haines, B. B.; Zhang, T.; Winter, C. G.; Jha, S.; Xu, Y.; Frazier, J.; Klinghoffer, R. A.; Leighton-Swayze, A.; Song, Y.; Ebbinghaus, S.; Baselga, J.
- Publisher
- American Association for Cancer Research; American Association for Cancer Research (AACR) (ISSN 1078-0432)
- Published
- 2014
- Field
- Medicine (Health Sciences)